G1 Therapeutics (NASDAQ:GTHX) had its target price raised by Needham & Company LLC to $76.00 in a report published on Tuesday, September 18th, The Fly reports. Needham & Company LLC currently has a buy rating on the stock.
Several other research firms also recently issued reports on GTHX. HC Wainwright reaffirmed a buy rating and set a $79.00 price target on shares of G1 Therapeutics in a research note on Monday, September 17th. BTIG Research initiated coverage on G1 Therapeutics in a research note on Monday, September 10th. They set a buy rating and a $80.00 price target for the company. Cowen reiterated a buy rating on shares of G1 Therapeutics in a research report on Thursday, August 9th. JPMorgan Chase & Co. lifted their price objective on G1 Therapeutics from $58.00 to $63.00 and gave the stock an overweight rating in a research report on Friday, August 10th. Finally, BidaskClub upgraded G1 Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday, August 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $74.50.
Shares of NASDAQ GTHX traded down $0.02 during mid-day trading on Tuesday, hitting $42.98. 279,513 shares of the company were exchanged, compared to its average volume of 278,142. G1 Therapeutics has a 1-year low of $18.03 and a 1-year high of $69.57. The company has a market cap of $1.75 billion, a PE ratio of -12.04 and a beta of -1.02.
G1 Therapeutics (NASDAQ:GTHX) last released its earnings results on Wednesday, August 8th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.01. On average, research analysts expect that G1 Therapeutics will post -2.68 EPS for the current year.
In other G1 Therapeutics news, insider Mark A. Velleca sold 5,000 shares of G1 Therapeutics stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $42.06, for a total value of $210,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Terry L. Murdock sold 3,519 shares of G1 Therapeutics stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $50.60, for a total value of $178,061.40. The disclosure for this sale can be found here. Insiders sold a total of 66,583 shares of company stock valued at $3,617,196 in the last 90 days. 15.92% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. United Services Automobile Association grew its holdings in shares of G1 Therapeutics by 2.7% during the 2nd quarter. United Services Automobile Association now owns 70,694 shares of the company’s stock worth $3,072,000 after purchasing an additional 1,882 shares during the period. Federated Investors Inc. PA purchased a new stake in shares of G1 Therapeutics during the 2nd quarter worth about $2,341,000. Cowen Inc. purchased a new stake in shares of G1 Therapeutics during the 2nd quarter worth about $4,778,000. TD Asset Management Inc. grew its holdings in shares of G1 Therapeutics by 26.4% during the 2nd quarter. TD Asset Management Inc. now owns 32,668 shares of the company’s stock worth $1,420,000 after purchasing an additional 6,832 shares during the period. Finally, California State Teachers Retirement System grew its holdings in shares of G1 Therapeutics by 64.6% during the 1st quarter. California State Teachers Retirement System now owns 20,576 shares of the company’s stock worth $762,000 after purchasing an additional 8,076 shares during the period. Institutional investors own 69.17% of the company’s stock.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Further Reading: Using the New Google Finance Tool
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.